WO2001025797A3 - Methods of evaluating whether a test agent is an agent affecting a leptin receptor - Google Patents

Methods of evaluating whether a test agent is an agent affecting a leptin receptor Download PDF

Info

Publication number
WO2001025797A3
WO2001025797A3 PCT/JP2000/006814 JP0006814W WO0125797A3 WO 2001025797 A3 WO2001025797 A3 WO 2001025797A3 JP 0006814 W JP0006814 W JP 0006814W WO 0125797 A3 WO0125797 A3 WO 0125797A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
methods
obr
test agent
subunit
Prior art date
Application number
PCT/JP2000/006814
Other languages
French (fr)
Other versions
WO2001025797A2 (en
Inventor
Toshio Kitamura
Yuki Isayama
Original Assignee
Sumitomo Chemical Co
Toshio Kitamura
Yuki Isayama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co, Toshio Kitamura, Yuki Isayama filed Critical Sumitomo Chemical Co
Priority to AU74515/00A priority Critical patent/AU7451500A/en
Publication of WO2001025797A2 publication Critical patent/WO2001025797A2/en
Publication of WO2001025797A3 publication Critical patent/WO2001025797A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods of evaluating whether a test agent is an agent affecting the activity of OBR. In said methods, a mammalian cell is cultured and exposed to the test agent. The mammalian cell has a polynucleotide encoding a chimeric receptor subunit comprising an extracellular domain of an OBR subunit, a transmembrane domain of a cytokine receptor subunit and an intracellular domain of a receptor subunit selected from a non-OBR homodimeric cytokine receptor subunit, gp130 and IL-2R β subunit; and has a proliferation dependency on OB. By measuring the proliferation of the mammalian cell, it can be evaluated whether the test agent is an agent which can affect the activity of OBR.
PCT/JP2000/006814 1999-10-06 2000-09-29 Methods of evaluating whether a test agent is an agent affecting a leptin receptor WO2001025797A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74515/00A AU7451500A (en) 1999-10-06 2000-09-29 Methods of evaluating whether a test agent is an agent affecting a leptin receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11/285396 1999-10-06
JP28539699 1999-10-06

Publications (2)

Publication Number Publication Date
WO2001025797A2 WO2001025797A2 (en) 2001-04-12
WO2001025797A3 true WO2001025797A3 (en) 2002-05-10

Family

ID=17691001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/006814 WO2001025797A2 (en) 1999-10-06 2000-09-29 Methods of evaluating whether a test agent is an agent affecting a leptin receptor

Country Status (2)

Country Link
AU (1) AU7451500A (en)
WO (1) WO2001025797A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271066A1 (en) * 2000-07-17 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method for screening ligand having biological activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004264A1 (en) * 1997-07-14 1999-01-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying modifiers of the leptin: leptin receptor interaction
WO1999023493A1 (en) * 1997-10-31 1999-05-14 The Rockefeller University Methods of identifying agents that modulate leptin activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004264A1 (en) * 1997-07-14 1999-01-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying modifiers of the leptin: leptin receptor interaction
WO1999023493A1 (en) * 1997-10-31 1999-05-14 The Rockefeller University Methods of identifying agents that modulate leptin activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENNET ET AL: "A role for leptin and its cognate receptor in hematopoiesis", CURRENT BIOLOGY, vol. 6, no. 9, - 17 July 1996 (1996-07-17), pages 1170 - 1180, XP000673008 *
HOUSEKNECHT, PORTOCARRERO: "Leptin and its receptors: regulators of whole-body energy homeostasis", DOMESTIC ANIMAL ENDOCRINOLOGY, vol. 15, no. 6, - November 1998 (1998-11-01), pages 457 - 475, XP001008003 *

Also Published As

Publication number Publication date
AU7451500A (en) 2001-05-10
WO2001025797A2 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
Nikas et al. Uterine pinopodes in peri-implantation human endometrium. Clinical relevance.
ES2183801T3 (en) COMPOSITIONS OF THE HUMAN NEURONAL NICOTINIC ACETILCOLINE RECEIVER AND PROCEDURES USING IT.
FI20031777A (en) Method, system, instrument and receiver for giving feedback
AU2002235772A1 (en) Determining the hydration status of a patient
WO2006023604A3 (en) Method and apparatus for network congestion control using queue control and one-way delay measurements
NZ553118A (en) Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DK1791865T3 (en) Cells expressing a modified T cell receptor
DE602007013068D1 (en) METHOD FOR EXAMINING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY
ES2057571T3 (en) PDGF-ALPHA RECEIVER.
DK1145002T4 (en) Bioluminescence test for agonists or antagonists for a calcium-coupled receptor
IL138593A0 (en) GFRα3 AND ITS USES
BR0108454A (en) Methods for identification and use of adenosine receptor antagonists a (2b) papa to mediate cell proliferation in mammals
WO2001025797A3 (en) Methods of evaluating whether a test agent is an agent affecting a leptin receptor
MY142857A (en) Treatment of incontinence with 5-ht2c receptor agonists
Fagan et al. Adenovirus encoded cyclic nucleotide-gated channels: a new methodology for monitoring cAMP in living cells
EP1879027A4 (en) Agent for preventing and treating pancreatitis
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004037160A3 (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
ATE273389T1 (en) Y-Y5 NEUROPEPTIDE RECEPTOR
EP0773289A3 (en) Asialoglycoprotein receptor derivatives and their use
EP1224861A4 (en) Animal with the mass expression of human gene and test method by using the animal
GR3025354T3 (en) AN -i(IN VITRO) METHOD OF EVALUATING THE EFFECTS OF A SUBSTANCE.
ES2167906T3 (en) NEW PROCEDURE FOR ANALYSIS OF GPIIB / IIIA PLAQUETARY RECEPTORS.
WO2005029035A3 (en) Methods of screening compositions for g protein-coupled receptor agonist activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase